Abstracts tagged "Therapy, complementary"

Abstract Number: 0025 • ACR Convergence 2023
Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Adam Cornish¹ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabinoid receptor 2 (CB2) is a member of the cannabinoid receptor family and is encoded by the CNR2 gene. CB2 receptors are found primarily…
Abstract Number: 0116 • ACR Convergence 2023
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Chary Lopez-Pedrera¹, Beatriz Vellón², Mª Angeles Aguirre³, Ismael Sanchez-Pareja², Laura Muñoz-Barrera², Tomás Cerdó², Pedro Segui², Christian Merlo-Ruiz², Desiree Ruiz-Vilchez², Maria del Carmen Abalos-Aguilera⁴, Nuria Barbarroja⁵, Alejandro Escudero Contreras⁶, Rafaela Ortega-Castro² and Carlos Perez-Sanchez⁷, ¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵University of Cordoba, Córdoba, Spain, ⁶Reina Sofia University Hospital, Córdoba, Spain, ⁷IMIBIC, Córdoba, Spain
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state, leading to arterial, venous, or microvascular thrombosis and accelerated atherosclerosis. Timely diagnosis…
Abstract Number: 0687 • ACR Convergence 2023
Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
Georgina Espigol-Frigole¹, Maria C Cid², Juliana Bordignon Draibe³, Maria Carmen Prados⁴, Elena Guillen⁵, Ana Huerta⁶, Javier Villacorta⁷, Cristina Vega⁸, Judith Martins⁹, Borja Gracia¹⁰ and Enrique Morales¹¹, ¹Autoimmune Diseases. Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Clinic Barcelona, Barcelona, Spain, ³Hospital Bellvitge, Barcelona, Spain, ⁴Hospital Torrecárdenas, Almeria, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Puerta de Hierro, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital La Paz, Madrid, Spain, ⁹Hospital de Getafe, Madrid, Spain, ¹⁰Hospital Lozano Blesa, Zaragoza, Spain, ¹¹Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: ANCA-associated vasculitis are chronic and relapsing diseases. Relapses are frequently associated with organ damage accrual as a consequence of disease activity or treatment-related side…
Abstract Number: 0206 • ACR Convergence 2022
Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada
kevin boehnke¹, Ying He¹, Tristin Smith¹, marc martel², david williams¹ and Mary-Ann Fitzcharles³, ¹University of Michigan, Ann Arbor, MI, ²McGill University, Montréal-Ouest, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Medical cannabis (MC) is increasingly used by persons with rheumatic conditions worldwide, although legal status varies by country. In Canada, MC has been federally…
Abstract Number: 0288 • ACR Convergence 2022
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Loïc Meudec¹, Pauline Richebé¹, Juliette Pascaud², Xavier Mariette³ and Gaetane Nocturne⁴, ¹Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, ²Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁴APHP, Le Kremlin Bicêtre, France
Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…
Abstract Number: 0551 • ACR Convergence 2022
Medical Cannabis Use by Rheumatology Patients According to Inflammatory versus Non-Inflammatory Condition
kevin boehnke¹, Tristin Smith¹, Ying He¹, marc martel², david williams¹ and Mary-Ann Fitzcharles³, ¹University of Michigan, Ann Arbor, MI, ²McGill University, Montréal-Ouest, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Persistent pain and poor sleep are common symptoms experienced by patients with rheumatic diseases. Medical cannabis (MC) may offer symptomatic relief and is increasingly…
Abstract Number: 0912 • ACR Convergence 2022
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Teresa Simon³, Stuart Kassan⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁴Colorado Arthritis Associates, Lakewood, CO, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been…
Abstract Number: 0922 • ACR Convergence 2022
Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
Nuria Barbarroja¹, Carlos Pérez-Sánchez¹, Laura Cuesta-Lopez¹, Miriam Ruiz-Ponce¹, Ivan Arias-de la Rosa¹, Antonio Gonzalez², Eva Perez Pampin³, Chamaida Plasencia-Rodriguez⁴, Ana Martinez-Feito⁴, Rafaela Ortega-Castro¹, Jerusalem Calvo-Gutierrez⁵, Alejandro Balsa⁶, Alejandro Escudero-Contreras¹, Eduardo Collantes¹ and Chary López-Pedrera⁷, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ³Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ⁴Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ⁶Hospital La Paz Institute for Health Research, Madrid, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of suffering cardiovascular disease. The analysis of the cardiovascular and cardiometabolic proteome in RA patients…
Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Alberto Sulli, Tamara Vojinovic, Lercara Adriano, Emanuele Gotelli, sabrina Paolino, Alessandri Elisa and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…
Abstract Number: 1044 • ACR Convergence 2022
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
cristina Valero-Martinez¹, Judith Font Urguelles², Meritxell Sallés³, BEATRIZ E. JOVEN⁴, Felipe Julio Ramirez Garcia⁵, Xavier Juanola⁶, Raquel Almodóvar⁷, ana Laiz⁸, Mireia Moreno⁹, Manel Pujol¹⁰, Luis Sala-Icardo¹¹, Santos Castañeda¹² and Rosario Garcia-Vicuña¹, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Althaia Xarxa Assistencial Universitària, Manresa, Spain, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Hospital Clínic, Barcelona, Spain, ⁶Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain, ⁷Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁸Unitat Territorial de Reumatologia Sant Pau-Dos de Maig, Barcelona, Spain, ⁹Hospital Universitari Parc Taulí, Sabadell, Spain, ¹⁰Hospital Universitario MútuaTerrassa, Terrassa, Spain, ¹¹Hospital Universitario de Torrejón de Ardoz, Madrid, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Combined biological or targeted therapy (CBTT) is rarely considered in clinical practice due to contraindication in guidelines, potential safety concerns and high costs. However,…
Abstract Number: 1174 • ACR Convergence 2022
Cellular Immunotherapy for Systemic Sclerosis
Chanhyuk Park¹, Rajan Bhandari², Jason Gunn³, Timothy Sullivan², Gretel Torres², Joana Murad³, Michael Whitfield⁴ and Patricia Pioli², ¹Geisel School of Medicine at Dartmouth, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Celdara Medical, Lebanon, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Pro-fibrotic macrophages (MØs) are implicated in the pathogenesis of systemic sclerosis (SSc). In prior work, we and others have shown that MØs derived from…
Abstract Number: 1227 • ACR Convergence 2022
Impact of Pain Sensitivity and Expectations on Predicting Response to Acupuncture in Fibromyalgia
Anne Murphy¹, Henry Buchtel¹, Erin Zhan¹, Steven E Harte¹, Ishtiaq Mawla¹, Eric Ichesco¹, Tony Larkin¹, Vitaly Napadow² and Richard E Harris¹, ¹University of Michigan, Ann Arbor, MI, ²Harvard Medical School, Boston, MA
Background/Purpose: Fibromyalgia (FM) is a common chronic pain condition for which acupuncture treatment is increasingly utilized. However, there is no universally accepted measure to predict…
Abstract Number: 1294 • ACR Convergence 2022
Translation and Cross-cultural Adaptation of the CORS into Spanish
Victoria Navarro-Compán¹, Diego Benavent², Andrea Jochems³, Dora Pascual-Salcedo³, Gijs Jochems⁴, Sofia Ramiro⁵, Wim van Lankveld⁶ and Chamaida Plasencia-Rodriguez⁷, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology Group, Hospital Universitario La Paz, Madrid, Spain, ⁴Promega Biotech Ibérica, Madrid, Spain, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶NA, Amsterdam, Netherlands, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Spain
Background/Purpose: Rheumatic diseases substantially affect the lives of patients, with complex associations between disease severity and self-perceived health status. In this regard, the Coping with…
Abstract Number: 1833 • ACR Convergence 2022
Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial
Hildrun Haibel¹, Joachim Sieper¹, Denis Poddubnyy², valeria Rios-Rodriguez³, Fabian Proft², Mikhail Protopopov⁴, Judith Rademacher⁴, Sabrina Igel⁵, Peter Martus⁶ and Christoph Stein⁵, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany, ⁶University Hospital Tübingen, Tübingen, Germany
Background/Purpose: The current standard of intraarticular therapy in patients with inflammatory arthritis (e.g. rheumatoid arthritis; RA) or inflammatory exacerbations of osteoarthritis (OA) is the injection…
Abstract Number: 1876 • ACR Convergence 2022
Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
Ana Campar¹, Ana Sá², Bárbara Oliveira² and António Marinho¹, ¹CENTRO HOSPITALAR UNIVERSITÁRIO DO PORTO, PORTO, Portugal, ²Centro Hospitalar Universitário do Porto, Porto, Portugal
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of systemic autoimmune disorders, comprising dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), inclusion…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].